MWZB found by PTO Analytics Firm to be Top 10 for Allowance Rate in PTO Chemical Technology Group

A PTO analytics firm (Juristat) recently found that Millen, White, Zelano & Branigan was among the Top 10 firms for allowance rate of patent applications...

Value in Underutilized Design Patents

Design patent protection is distinct from utility patent protection. Design patents protect the ornamental features of an article of manufacture rather than its utilitarian features....

Diagnostic Peptide Panels Patent-Ineligible?

Oxford Immunotec Ltd. v. Qiagen, Inc. et al., pending in the U.S. District Court, D. Mass. (Case 1:15-cv-13124-NMG), likely has a long way to go before...

New After Final Program at USPTO

In an attempt to reduce the number of appeals and RCE filings, and streamline after final practice, the USPTO launched a new pilot program on...

USPTO Announces a Cancer Immunotherapy Pilot Program

In February The White House announced a national $1 billion initiative to achieve ten years’ worth of cancer research in the next five years to...

New Life Sciences Examples to Help Examiners (and Applicants) Interpret and Apply the Subject Matter Eligibility Analysis under 35 USC § 101 in View of SCOTUS and CAFC Case Law: Nothing Much New

 On May 6, 2016, the USPTO issued several documents (http://www.uspto.gov/patent/laws-and-regulations/examination-policy/2014-interim-guidance-subject-matter-eligibility-0), including new Subject Matter Eligibility Examples for Life Sciences (including one that is directed to...

Are Proactive Portfolio Reviews Needed After 2015 Gilead Double Patenting Decision?

Gilead Sciences, Inc., Hoffmann-La Roche, Inc., F. Hoffmann-La Roche, Ltd., and Genentech, Inc., v.Natco Pharma Ltd.and Natco Pharma, Inc., 753 F.2d 1208 (Fed. Cir. 2014,...
1 9 10 11 12 13 17

Categories

MWZB Newsletter Signup

Subscribe